A Prospective Registration Study of Pembrolizumab in the First Line Therapy for PD-L1 CPS≥20 Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in China
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 10 Feb 2021 Status changed from not yet recruiting to recruiting.
- 10 Feb 2021 Status changed from not yet recruiting to recruiting.
- 09 Feb 2021 New trial record